Literature DB >> 18175071

The Met tyrosine kinase receptor in development and cancer.

Alessandra Gentile1, Livio Trusolino, Paolo M Comoglio.   

Abstract

Met is a tyrosine kinase receptor, encoded by an oncogene, whose crucial role has been elucidated during the last two decades. The complex biological program triggered by Met has been dissected and its biological relevance in both physiology and pathology has been proven. Met supports a morphogenetic program, known as invasive growth, taking place both during embryogenesis and adulthood. In tumors Met is often aberrantly activated, giving rise to the pathological counterpart of the invasive growth program: cancer progression towards metastasis. Several approaches have been recently developed to interfere with the tumorigenic and metastatic processes triggered by Met.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175071     DOI: 10.1007/s10555-007-9107-6

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  137 in total

Review 1.  Cutting edge in medical management of cutaneous oncology.

Authors:  Kim Chong; Adil Daud; Susana Ortiz-Urda; Sarah T Arron
Journal:  Semin Cutan Med Surg       Date:  2012-06

2.  Topographic gene expression in the sinonasal cavity of patients with chronic sinusitis with polyps.

Authors:  Michael P Platt; Zachary M Soler; Shyan-Yuan Kao; Ralph Metson; Konstantina M Stankovic
Journal:  Otolaryngol Head Neck Surg       Date:  2011-07       Impact factor: 3.497

3.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

4.  New horizons in melanoma treatment: targeting molecular pathways.

Authors:  Christopher W M Soon; Alain P Algazi; Edward N Cha; Adil I Daud
Journal:  Ochsner J       Date:  2010

5.  Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Authors:  Paolo Giannoni; Gabriella Pietra; Giorgia Travaini; Rodolfo Quarto; Genti Shyti; Roberto Benelli; Laura Ottaggio; Maria Cristina Mingari; Simona Zupo; Giovanna Cutrona; Ivana Pierri; Enrico Balleari; Alessandra Pattarozzi; Marco Calvaruso; Claudio Tripodo; Manlio Ferrarini; Daniela de Totero
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 9.941

Review 6.  Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer.

Authors:  Ali Fatehi Hassanabad; Kelsey T MacQueen
Journal:  Cell Oncol (Dordr)       Date:  2020-10-30       Impact factor: 6.730

Review 7.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

8.  EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Swapna Asuthkar; Bharathi Gorantla; Andrew J Tsung
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

9.  Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells.

Authors:  Richard Buus; Monica Faronato; Dean E Hammond; Sylvie Urbé; Michael J Clague
Journal:  Curr Biol       Date:  2009-08-20       Impact factor: 10.834

10.  Decorin is a novel antagonistic ligand of the Met receptor.

Authors:  Silvia Goldoni; Ashley Humphries; Alexander Nyström; Sampurna Sattar; Rick T Owens; David J McQuillan; Keith Ireton; Renato V Iozzo
Journal:  J Cell Biol       Date:  2009-05-11       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.